<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110524006582N37</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-09</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of topical ointment of Propolis on severity of episiotomy pain and wound healing</public_title>
      <acronym></acronym>
      <scientific_title>The effect of topical ointment of Propolis on severity of episiotomy pain and wound healing: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68181</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling will be done based on the purpose, the sequence of allocation in the intervention groups will be using a computer randomization program and with an allocation ratio of 1:1. In order to hide the allocation (allocation concealment), the type of ointment for each participant (drug or placebo) will be determined by a person not involved in the study using a randomizer, and a numbered label will be placed on the ointments, Blinding description: Participants, researcher and data analyst will be blinded. Both drug and placebo will be completely similar in terms of color, size and shape and will be presented in similar packages. In addition to the person determining the sequence of placement of people in the groups, the only person who will know the type of drug prescribed will be the research assistant, and the participants, researcher, data collectors and analysts will not be informed.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Severity of episiotomy pain. Condition 2: Episiotomy wound healing.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants in the intervention group will use 2 cm (1 knuckle length) ointment on the ٍEpisiotomy site twice a day, 12 hours apart, for ten days. The contents of the ointment will include Propolis and Oserin (Vaseline and a little Lanolin). Propolis will be made from Royal Shahd Pirlanta bee products company, which is a beehive breeding place in Azerbaijan region, and Oserin will be made from Dr. Shahtalebi cosmetic company. Intervention 2: Control group: Participants in the control group will use 2 cm (1 knuckle length) ointment on the episiotomy site 2 times a day, 12 hours apart, for ten days. The prepared ointment base will be used as a placebo ointment without Propolis. If there is a need to adjust the color of the ointment, the approved pharmaceutical color will be used to match the color of the placebo and Propolis ointment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Participants data is confidential.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoomeh Rafat Nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3478 5229</telephone>
        <email>Rafatniamasume@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahin Kamali Fard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery school, Shariati street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9876598765</zip>
        <telephone>+98 41 3524 5181</telephone>
        <email>Kamalifardm@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gravid one and two women
Living in Tabriz city
Willingness and possibility of the mother to go to Alzahra and Taleghani hospitals on the 10th day
Vaginal delivery with mediolateral incision</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Prolonged rupture of the amniotic sac (more than 18 hours)
Use of special drugs such as anti-inflammatory and anticoagulant drugs
Addiction to alcohol or drugs
History of diseases interfering with wound healing such as systemic, cardiac, renal, pulmonary diseases, coagulation disorder, immunodeficiency, connective tissue disorder, diabetes, anemia, mental illness, hemophilia (based on medical records)
Abnormal postpartum bleeding
Preterm labor
Allergy to propolis
Large or extended episiotomy (third or fourth degree tear and episiotomy cut length greater than 3-4 cm)
History of surgery or visible lesions in the perineum
Severe anemia (hemoglobin less than 7 grams per deciliter)
Other tears in addition to episiotomy, such as urethral tears
Non-continuing cooperation of participants
Incomplete participation that is not possible to achieve results</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants in the intervention group will use 2 cm (1 knuckle length) ointment on the ٍEpisiotomy site twice a day, 12 hours apart, for ten days. The contents of the ointment will include Propolis and Oserin (Vaseline and a little Lanolin). Propolis will be made from Royal Shahd Pirlanta bee products company, which is a beehive breeding place in Azerbaijan region, and Oserin will be made from Dr. Shahtalebi cosmetic company.</i_keyword>
      <i_keyword>Control group: Participants in the control group will use 2 cm (1 knuckle length) ointment on the episiotomy site 2 times a day, 12 hours apart, for ten days. The prepared ointment base will be used as a placebo ointment without Propolis. If there is a need to adjust the color of the ointment, the approved pharmaceutical color will be used to match the color of the placebo and Propolis ointment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain level of episiotomy. Timepoint: At the beginning of the study (before the start of the intervention) and on the 10th day after delivery. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Episiotomy wound healing rate. Timepoint: At the beginning of the study (before the start of the intervention) and on the 10th day after delivery. Method of measurement: Redness, Edema, Ecchymosis, Discharge, Approximation scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-28</approval_date>
        <contact_name>Medical Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Research department, third floor, central construction number 2, Tabriz university of medical science, Azadi avenue Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
